Skip to content

    Alkem Lab

    ALKEM
    Healthcare·12 Aug 2025
    Management Summary

    Alkem Lab reported a strong Q1 FY26, with double-digit revenue and profit growth driven by robust performance in both India and international markets. The company's EBITDA margin expanded to 21.9%, reflecting disciplined strategy execution. While new initiatives like MedTech are expected to incur initial losses, management expressed confidence in their long-term growth potential and maintained full-year guidance despite anticipated higher R&D and opex in later quarters.

    Highlights

    5

    • Total revenue grew 11.2% Y-o-Y to INR33,711 million, driven by strong top-line growth across domestic and international markets.

    • EBITDA margin improved to 21.9%, with EBITDA growing 21.4% Y-o-Y to INR7,391 million.

    • Net profit increased by 21.8% Y-o-Y to INR6,643 million, reflecting an improved gross margin and better EBITDA profile.

    • India business outperformed the Indian Pharmaceutical Market (IPM) by 120 basis points, growing 9.7% Y-o-Y against IPM's 8.5%.

    • Commencement of revenue generation from the Alkem MedTech initiative, with positive initial customer response.

    Concerns

    3

    • U.S. business experienced a 3-4% Y-o-Y price drop in Q1 FY26, impacting margins.

    • MedTech business is expected to incur losses of INR40-50 crores for FY26 and FY27 before breaking even in FY28.

    • Higher R&D expenses and operational expenditure for new initiatives (like the U.S. biotech plant) are anticipated in Q3 and Q4 FY26, potentially impacting margins in those quarters.

    What Changed2

    vs Q2 FY26

    Guidance items15 → 12 (-3)Risks discussed3 → 4 (+1)

    Key financials

    Single quarter

    06 metrics
    1. 01Total Revenue33,711 Mn+11.2%YoY
    2. 02EBITDA7,391 Mn+21.4%YoY
    3. 03EBITDA Margin21.9%
    4. 04Net Profit6,643 Mn+21.8%YoY
    5. 05R&D Expenses1,184 Mn

    Segment breakdown

    • India Sales22,656 Mn68.3%
    • U.S. Business6,982 Mn21.0%
    • Non-U.S. Business3,556 Mn10.7%
    Donut· Share of Revenue

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹750 crores

    M&A

    Adroit

    acquisition · closed

    Guidance & targets

    12
    CategoryTargetPriority
    Profitability
    Overall Guidance
    Maintain current guidance
    		Medium
    Profitability
    MedTech Breakeven
    Breakeven
    		High
    Profitability
    MedTech Losses
    INR40-50 crores
    		High
    R&D
    R&D Expenses as % of Revenue
    4.5% to 5%
    		High
    Revenue
    MedTech Annual Run Rate (ARR)
    INR40-50 crores
    		Medium
    Revenue
    India Business Growth vs. IPM
    100-150 basis points faster
    		High
    Revenue
    U.S. Business Growth
    Mid-single-digit to higher single-digit
    		Medium
    Margin
    Gross Margin
    64%
    		High
    Margin
    Operational EBITDA Margin Improvement
    1% annually
    		High
    Opex
    Enzene CDMO Facility Opex
    INR50 crores
    		High
    Opex
    MedTech Opex
    INR25-30 crores
    		High
    Tax
    Effective Tax Rate
    13% to 15%
    		High

    MedTech Revenue Ramp-up

    Next quarter (Q2 FY26) and coming quarters
    CurrentINR2.5 crores in Q1 FY26
    TargetProgress towards INR40-50 crores ARR by year-end

    Why it matters

    Tracking the growth trajectory of the new MedTech business is crucial for assessing its long-term potential and contribution.

    So, see, MedTech business, we've just started. So, our first quarter revenue is around INR2.5 crores, which is very minimal. But we are pretty confident with the way we have started that business. And in the initial months itself, the uptake has been -- the response of customers has been quite positive. So, we are bullish about that strategy and hope to scale it in the coming quarters.

    How to verify

    key_financials.segment_breakdown[name='India Sales'].metrics[label='Revenue'] (as MedTech is part of India business)

    Risks & concerns

    4
    RiskSeverity

    U.S. Price Erosion

    U.S. market experienced a 3-4% Y-o-Y price drop in Q1 FY26, which partially offset margin improvements from better mix. — Management acknowledged

    medium

    Geopolitical Scenario and Tariff Discussions

    Uncertainty regarding geopolitical scenarios and potential tariffs could impact the U.S. market, though management stated they would adapt as details emerge. — Management acknowledged

    medium

    Initial Losses from MedTech Business

    The new MedTech business is projected to incur losses of INR40-50 crores in FY26 and FY27 before achieving breakeven in FY28. — Management acknowledged

    low

    Increased Opex from New Initiatives in H2 FY26

    Higher R&D expenses and operational costs for the U.S. biotech plant, which will become fully operational in Q3/Q4, are expected to impact margins in the latter half of FY26. — Management acknowledged

    medium

    Q&A highlights

    8

    “But I would say, at this stage, it is just 1 quarter of the year that has gone by. So, I find it a little too early to revise the guidance upward, but I can clearly tell you if the year progresses, the way we are seeing for some more time, then definitely, we would overachieve on the guidance that we have given.”

    Analyst probed for an upward revision to FY26 guidance given strong Q1, but management chose to maintain current guidance, citing early stage of the year and potential future expenses.

    asked by Kunal Dhamesha

    2 min read5 chapters

    Detailed Narrative

    01

    Strong Q1 Performance & Growth Drivers

    Alkem Laboratories reported a robust start to FY26, with total revenue from operations growing 11.2% year-on-year to INR33,711 million. This growth was fueled by strong performances in both domestic and international markets. India sales increased by 12% to INR22,656 million, while the U.S. business grew 8.8% to INR6,982 million, and non-U.S. business saw a 9.1% rise to INR3,556 million. The company also outperformed the Indian Pharmaceutical Market (IPM) by 120 basis points, achieving 9.7% growth against IPM's 8.5%.

    02

    Strategic Focus on New Initiatives & Non-U.S. Markets

    The company is strategically accelerating its focus on non-U.S. business segments and new initiatives like Alkem MedTech. The MedTech business commenced revenue generation in Q1 FY26, contributing INR2.5 crores, with an anticipated annual run rate of INR40-50 crores by year-end. While MedTech is expected to incur losses of INR40-50 crores in FY26 and FY27, management targets breakeven by FY28. Additionally, the CDMO facility is expected to be fully operational by Q4 FY26, with an estimated opex of INR50 crores per quarter.

    03

    Gross Margin Dynamics & R&D Spend

    EBITDA grew significantly by 21.4% year-on-year to INR7,391 million, resulting in an improved EBITDA margin of 21.9%. This was attributed to strong top-line growth and an improved gross margin, partly due to lower API prices and a higher domestic contribution. Despite the strong Q1, management maintained its full-year gross margin guidance of 64%. R&D expenses for the quarter were INR1,184 million, representing 3.5% of total revenue, with management clarifying that the lower Q1 percentage is due to phasing, expecting higher R&D in later quarters to meet the annual guidance of 4.5-5%.

    04

    Capital Allocation & M&A Strategy

    Alkem's capital allocation for FY26 is planned at around INR750 crores, primarily directed towards biotech and CDMO opportunities. The company completed the acquisition of Adroit in Q1 FY26, which contributed INR15 crores to revenue. Management emphasized that they are not limited by 'ticket size' for M&A, particularly in the chronic segment, and are open to acquisitions that add strategic value and can be grown effectively, leveraging their strong cash reserves.

    05

    U.S. Business Outlook & Tariff Uncertainty

    The U.S. business grew 8.8% year-on-year to INR6,982 million, despite a 3-4% price erosion in Q1 FY26. The company launched sacubitril/valsartan in July, with its impact expected to be seen in Q2 FY26 results. Management maintained its mid-single-digit to higher single-digit growth guidance for the U.S. market. Regarding potential tariffs, management views it as a hypothetical question, stating they would assess and adapt their strategy, including passing on costs or seeking backward integration, once specific details emerge.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.